UBS Group’s Agios Pharmaceuticals AGIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
– Sell
-12,500
Closed -$542K – 8938
2020
Q4
$542K Hold
12,500
– – ﹤0.01% 4540
2020
Q3
$438K Buy
+12,500
New +$548K ﹤0.01% 4296
2020
Q2
– Sell
-9,300
Closed -$330K – 7898
2020
Q1
$330K Buy
+9,300
New +$430K ﹤0.01% 4319
2015
Q1
– Sell
-1,400
Closed -$157K – 8735
2014
Q4
$157K Buy
+1,400
New +$125K ﹤0.01% 5267

Other funds holding AGIO

UBS Group's AGIO Position: Q3 2026 in Review

UBS Group reduced its Agios Pharmaceuticals (AGIO) stake by 6.5% in Q3 2026, selling an estimated $2.26M and leaving 921,337 shares worth $30.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2196.

UBS Group first reported a position in AGIO in Q4 2014 and has held it in 48 quarters since. The position peaked at $36.6M in Q2 2026. 243 funds tracked by Wall St. Rank hold AGIO as of Q3 2026.

  • UBS Group held 921,337 shares of Agios Pharmaceuticals worth $30.6M as of Q3 2026.
  • UBS Group sold 64,494 Agios Pharmaceuticals shares in Q3 2026, an estimated $2.26M.
  • Agios Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #2196 holding.
  • UBS Group first reported a position in Agios Pharmaceuticals in Q4 2014 and has held it in 48 quarters since.
  • UBS Group's Agios Pharmaceuticals position peaked at $36.6M in Q2 2026.
  • 243 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.